| Hannah Elisabeth Underdahl, RN, MSN, CNM, WHNP | |
|
6565 W Emerald St, Boise, ID 83704-8737 | |
| (208) 514-2510 | |
| (208) 375-2217 |
| Full Name | Hannah Elisabeth Underdahl |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 6565 W Emerald St, Boise, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073952016 | NPI | - | NPPES |
| 1073952016 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | CNM69A (Idaho) | Primary |
| 363LW0102X | Nurse Practitioner - Women's Health | NP1323A (Idaho) | Secondary |
| Entity Name | Full Circle Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841490075 PECOS PAC ID: 6709986797 Enrollment ID: O20070924000618 |
News Archive
Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.
The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.
A study by National Institutes of Health scientists in the Office of Disease Prevention examined NIH grants and cooperative agreements during fiscal years 2012 through 2017 to determine the alignment of prevention research across NIH institutes and centers with leading risk factors and causes of death and disability in the United States.
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Elisabeth Underdahl, RN, MSN, CNM, WHNP 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 514-2500 | Hannah Elisabeth Underdahl, RN, MSN, CNM, WHNP 6565 W Emerald St, Boise, ID 83704-8737 Ph: (208) 514-2510 |
News Archive
Quincy Bioscience, a research-based biotechnology company, announced the issuance of United States patent No.7,671,015. The patent covers the use of aequorin-containing compounds for the purpose of preventing and alleviating symptoms and disorders related to calcium imbalance.
The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.
A study by National Institutes of Health scientists in the Office of Disease Prevention examined NIH grants and cooperative agreements during fiscal years 2012 through 2017 to determine the alignment of prevention research across NIH institutes and centers with leading risk factors and causes of death and disability in the United States.
In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage.
› Verified 7 days ago
Sophie Tobeck, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 207 W Washington St, Boise, ID 83702 Phone: 208-343-2079 Fax: 208-343-6828 | |
Ashley Rochelle Lanham, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 207 W Washington St, Boise, ID 83702 Phone: 208-343-2079 Fax: 208-343-6868 | |
Mrs. Megan Ashley Kitterman, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 333 N 1st St Ste 260, Boise, ID 83702 Phone: 208-345-3136 Fax: 208-345-0984 | |
Ms. Rebekah G Fayette, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1072 N Liberty, Suite 100, Boise, ID 83704 Phone: 208-302-1200 Fax: 208-302-1255 | |
Margaret L Widener, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 6140 Curtisian Ave, Suite 100, Boise, ID 83704 Phone: 208-302-1200 Fax: 208-302-1255 | |
Georgianna T Ainslie, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 5966 Curtisian Ave, Boise, ID 83704 Phone: 208-375-8100 Fax: 208-373-2643 |